BioSpace News Archive

University Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy (GA).

Novartis Pharmaceuticals Canada Inc. is pleased to announce that Luxturna® is now funded by the Ontario government for the treatment of adults and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed mutations in both copies of the RPE65 gene and who have sufficient, viable retinal cells.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Cowen 43rd Annual Health Care Conference at 9:50 a.m. ET on Wednesday, March 8, 2023.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter ended December 31, 2022, after the financial markets close on Wednesday, March 15, 2023.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced financial results for its fourth quarter and full-year ended December 31, 2022.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced that President and Chief Executive Officer Michael Egholm, PhD, will present at the Cowen Health Care Conference on Wednesday, March 8, 2023, at 12:50 p.m. ET.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the year ended December 31, 2022.

Cytokinetics, Incorporated reported financial results for the fourth quarter and full year 2022. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2022 was $389.0 million or $4.33 per share.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the fourth quarter and the year ended December 31, 2022.

Conformis, Inc. an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the fourth quarter and year ended December 31, 2022.